Logo image of IMUX

IMMUNIC INC (IMUX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IMUX - US4525EP1011 - Common Stock

0.5492 USD
+0.02 (+2.9%)
Last: 1/2/2026, 10:13:21 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IMUX. IMUX was compared to 530 industry peers in the Biotechnology industry. While IMUX seems to be doing ok healthwise, there are quite some concerns on its profitability. IMUX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IMUX had negative earnings in the past year.
In the past year IMUX has reported a negative cash flow from operations.
IMUX had negative earnings in each of the past 5 years.
In the past 5 years IMUX always reported negative operating cash flow.
IMUX Yearly Net Income VS EBIT VS OCF VS FCFIMUX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -253.16%, IMUX is not doing good in the industry: 90.38% of the companies in the same industry are doing better.
IMUX has a Return On Equity of -981.49%. This is in the lower half of the industry: IMUX underperforms 78.87% of its industry peers.
Industry RankSector Rank
ROA -253.16%
ROE -981.49%
ROIC N/A
ROA(3y)-170.85%
ROA(5y)-121.12%
ROE(3y)-324.95%
ROE(5y)-215.14%
ROIC(3y)N/A
ROIC(5y)N/A
IMUX Yearly ROA, ROE, ROICIMUX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMUX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMUX Yearly Profit, Operating, Gross MarginsIMUX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

IMUX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IMUX has more shares outstanding
There is no outstanding debt for IMUX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMUX Yearly Shares OutstandingIMUX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IMUX Yearly Total Debt VS Total AssetsIMUX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

IMUX has an Altman-Z score of -27.28. This is a bad value and indicates that IMUX is not financially healthy and even has some risk of bankruptcy.
IMUX has a worse Altman-Z score (-27.28) than 85.28% of its industry peers.
IMUX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.28
ROIC/WACCN/A
WACCN/A
IMUX Yearly LT Debt VS Equity VS FCFIMUX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 1.31 indicates that IMUX should not have too much problems paying its short term obligations.
IMUX has a Current ratio of 1.31. This is amonst the worse of the industry: IMUX underperforms 82.26% of its industry peers.
IMUX has a Quick Ratio of 1.31. This is a normal value and indicates that IMUX is financially healthy and should not expect problems in meeting its short term obligations.
IMUX has a worse Quick ratio (1.31) than 81.51% of its industry peers.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 1.31
IMUX Yearly Current Assets VS Current LiabilitesIMUX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

IMUX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.52%, which is quite impressive.
EPS 1Y (TTM)32.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.97% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y36.69%
EPS Next 2Y27.48%
EPS Next 3Y15.44%
EPS Next 5Y16.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMUX Yearly Revenue VS EstimatesIMUX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
IMUX Yearly EPS VS EstimatesIMUX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMUX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMUX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMUX Price Earnings VS Forward Price EarningsIMUX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMUX Per share dataIMUX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as IMUX's earnings are expected to grow with 15.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.48%
EPS Next 3Y15.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMUX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

IMMUNIC INC

NASDAQ:IMUX (1/2/2026, 10:13:21 AM)

0.5492

+0.02 (+2.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)02-19 2026-02-19/amc
Inst Owners37.78%
Inst Owner Change-14%
Ins Owners1.05%
Ins Owner Change0%
Market Cap66.06M
Revenue(TTM)N/A
Net Income(TTM)-103.05M
Analysts85.33
Price Target5.48 (897.82%)
Short Float %4.8%
Short Ratio4.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.54%
Min EPS beat(2)-18.84%
Max EPS beat(2)23.91%
EPS beat(4)1
Avg EPS beat(4)-0.51%
Min EPS beat(4)-18.84%
Max EPS beat(4)23.91%
EPS beat(8)3
Avg EPS beat(8)-0.39%
EPS beat(12)4
Avg EPS beat(12)-10.15%
EPS beat(16)7
Avg EPS beat(16)-6.64%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-29.28%
EPS NQ rev (1m)1.3%
EPS NQ rev (3m)28.8%
EPS NY rev (1m)15.14%
EPS NY rev (3m)12.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.29
P/tB 6.29
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -253.16%
ROE -981.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-170.85%
ROA(5y)-121.12%
ROE(3y)-324.95%
ROE(5y)-215.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 95.03%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.31
Quick Ratio 1.31
Altman-Z -27.28
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)211.81%
Cap/Depr(5y)217.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.83%
EPS Next Y36.69%
EPS Next 2Y27.48%
EPS Next 3Y15.44%
EPS Next 5Y16.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.46%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNIC INC / IMUX FAQ

Can you provide the ChartMill fundamental rating for IMMUNIC INC?

ChartMill assigns a fundamental rating of 2 / 10 to IMUX.


Can you provide the valuation status for IMMUNIC INC?

ChartMill assigns a valuation rating of 0 / 10 to IMMUNIC INC (IMUX). This can be considered as Overvalued.


Can you provide the profitability details for IMMUNIC INC?

IMMUNIC INC (IMUX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for IMMUNIC INC?

The Earnings per Share (EPS) of IMMUNIC INC (IMUX) is expected to grow by 36.69% in the next year.